Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages
Primary results from the persevERA study on the numerical improvement in progression-free survival observed with first-line giredestrant plus palbociclib in advanced, endocrine-sensitive disease
Overall, nine approved and investigational medicines, including bispecific antibodies, antibody-drug conjugates and brain-permeable molecules, with ASCO data targeting urgent needs in breast, blood, lung and other cancers
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2 in Chicago.
